Arch Biopartners Inc.
Arch Biopartners Inc.
Your view on ARCH.V
Overview
What the company does, where it operates, and who runs it.
About Arch Biopartners Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard Gabriel Muruve
- Headquarters
- 27 Street Clair Avenue East, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard Gabriel Muruve
- Headquarters
- 27 Street Clair Avenue East, Toronto, ON, CA
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19.
The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Arch Biopartners Inc., and the rating behind it. ARCH.V last traded at C$0.73; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Arch Biopartners Inc.. Starting points for Arch Biopartners Inc.: EPS -C$0.04, beta 1.97 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Arch Biopartners Inc.. Arch Biopartners Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Arch Biopartners Inc.. Trailing twelve-month EPS for Arch Biopartners Inc. stands at -C$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Arch Biopartners Inc.. Arch Biopartners Inc. has reported as a listed company since 2002. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Arch Biopartners Inc. valued side by side against its closest peers. Arch Biopartners Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Arch Biopartners Inc., and how their positions are changing. At a C$48.2M market value, institutional positions materially move Arch Biopartners Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Arch Biopartners Inc. executives and directors. Shares of Arch Biopartners Inc. have traded between C$0.65 and C$1.43 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Arch Biopartners Inc.. Arch Biopartners Inc. is a C$48.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Arch Biopartners Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Arch Biopartners Inc.. Coverage tracks Arch Biopartners Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.